Monte Rosa Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Monte Rosa Therapeutics, Inc. (GLUE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.88 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 314.27K shares, a 27.55% increase year-over-year.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.57M shares, a 27.93% decline year-over-year.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 73.40K shares, a 20.15% decline year-over-year.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 27.80K shares, a 76.24% decline year-over-year.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.91M shares, a 28.82% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.04M shares, a 10.36% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.39M shares, a 51.41% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.24M shares, a 43.02% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 314.27K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 2.88M shares 10-Q · filed 2026-08-06 | 2.96M shares derived: sum of 3 quarters · filed 2026-08-06 | 2.98M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 2.57M shares 10-Q · filed 2026-05-07 | 2.64M shares derived: sum of 2 quarters · filed 2026-05-07 | 2.67M shares derived: sum of 3 quarters · filed 2026-05-07 | 2.92M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 73.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 101.20K shares derived: sum of 2 quarters · filed 2026-03-17 | 347.60K shares derived: sum of 3 quarters · filed 2026-03-17 | 3.91M shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 27.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 274.20K shares derived: sum of 2 quarters · filed 2025-11-06 | 3.84M shares 10-Q · filed 2025-11-06 | 3.93M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 246.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 3.81M shares 10-Q · filed 2025-08-07 | 3.90M shares derived: sum of 3 quarters · filed 2025-08-07 | 4.02M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 3.57M shares 10-Q · filed 2025-05-08 | 3.66M shares derived: sum of 2 quarters · filed 2025-05-08 | 3.77M shares derived: sum of 3 quarters · filed 2025-05-08 | 4.06M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 91.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 208.93K shares derived: sum of 2 quarters · filed 2025-03-20 | 492.73K shares derived: sum of 3 quarters · filed 2025-03-20 | 3.04M shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 117.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 400.80K shares derived: sum of 2 quarters · filed 2024-11-07 | 2.95M shares 10-Q · filed 2024-11-07 | 3.09M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 283.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 2.83M shares 10-Q · filed 2024-08-08 | 2.98M shares derived: sum of 3 quarters · filed 2024-08-08 | 3.27M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 2.54M shares 10-Q · filed 2024-05-09 | 2.69M shares derived: sum of 2 quarters · filed 2024-05-09 | 2.99M shares derived: sum of 3 quarters · filed 2024-05-09 | 3.26M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 146.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 445.82K shares derived: sum of 2 quarters · filed 2024-03-14 | 716.08K shares derived: sum of 3 quarters · filed 2024-03-14 | 3.39M shares 10-K · filed 2024-03-14 |
| 2023-09-30 | 299.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 569.45K shares derived: sum of 2 quarters · filed 2023-11-09 | 3.24M shares 10-Q · filed 2023-11-09 | 3.52M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 270.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 2.94M shares 10-Q · filed 2023-08-10 | 3.23M shares derived: sum of 3 quarters · filed 2023-08-10 | 3.34M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 2.67M shares 10-Q · filed 2023-05-11 | 2.96M shares derived: sum of 2 quarters · filed 2023-05-11 | 3.06M shares derived: sum of 3 quarters · filed 2023-05-11 | 3.24M shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 283.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 392.50K shares derived: sum of 2 quarters · filed 2023-03-16 | 566.00K shares derived: sum of 3 quarters · filed 2023-03-16 | 2.24M shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 109.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 282.90K shares derived: sum of 2 quarters · filed 2022-11-10 | 1.95M shares 10-Q · filed 2022-11-10 | 2.07M shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 173.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 1.85M shares 10-Q · filed 2022-08-11 | 1.96M shares derived: sum of 3 quarters · filed 2022-08-11 | 1.96M shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 1.67M shares 10-Q · filed 2022-05-11 | 1.79M shares derived: sum of 2 quarters · filed 2022-05-11 | 1.79M shares derived: sum of 3 quarters · filed 2022-05-11 | |
| 2021-12-31 | 115.03K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 118.52K shares derived: sum of 2 quarters · filed 2022-03-29 | 3.93M shares 10-K · filed 2022-03-29 | |
| 2021-09-30 | 3.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 3.81M shares 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | 3.81M shares 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |